Anticipated Barriers to Sustained Engagement in Treatment With Medications for Opioid Use Disorder After Release From Incarceration

被引:5
|
作者
Kaplowitz, Eliana [1 ,2 ]
Truong, Ashley [3 ]
Macmadu, Alexandria [1 ,4 ]
Berk, Justin [4 ,5 ]
Martin, Harrison [1 ,6 ]
Burke, Caroline [7 ]
Rich, Josiah D. [1 ,2 ,5 ,8 ,10 ]
Brinkley-Rubinstein, Lauren [1 ,9 ]
机构
[1] Miriam Hosp, Ctr Hlth Justice Transformat, Providence, RI USA
[2] Rhode Isl Hosp, Ctr Biomed Res Excellence Opioids & Overdose, Providence, RI USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA
[4] Rhode Isl Dept Correct, Cranston, RI USA
[5] Brown Univ, Sch Med, Providence, RI USA
[6] Wesleyan Univ, Smith Coll, Middletown, CT USA
[7] Smith Coll, Northampton, MA USA
[8] Brown Univ Sch Publ Hlth, Dept Epidemiol, Providence, RI USA
[9] Univ North Carolina Chapel Hill, Dept Social Med, Chapel Hill, NC USA
[10] Miriam Hosp, 164 Summit Ave, Providence, RI 02906 USA
关键词
medication for opioid use disorder; treatment retention; incarceration; reentry barriers; METHADONE; PRISON; DEATH; STATE; RISK;
D O I
10.1097/ADM.0000000000001029
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundAlthough the burden of opioid use disorder is disproportionately high among persons who are incarcerated, medications for opioid use disorder are often unavailable in correctional settings. The Rhode Island Department of Corrections provides all 3 classes of medications for opioid use disorder to clinically eligible persons who are incarcerated. Despite a decrease in fatal overdoses among persons with recent criminal legal system involvement since the program's implementation, barriers to continued engagement in treatment after release from incarceration still exist.MethodsWe conducted 40 semistructured, qualitative interviews with people who were incarcerated and enrolled in the comprehensive medications for opioid use disorder program at the Rhode Island Department of Corrections. Analysis applied a general, inductive approach using NVivo 12.ResultsParticipants discussed barriers to treatment engagement before incarceration, as well as anticipated barriers to medications to treat opioid use disorder continuation after release from incarceration. Structural factors including housing, health insurance, transportation, and the treatment program structure, as well as social factors such as social support networks were perceived to influence retention in medications to treat opioid use disorder post-release.ConclusionOur findings suggest that people with opioid use disorder who are incarcerated encounter unique challenges upon community reentry. Addressing structural factors that pose barriers to post-release engagement is essential to sustaining retention. We recommend utilization of peer recovery specialists to alleviate some of the stress of navigating the structural barriers identified by participants.
引用
收藏
页码:54 / 59
页数:6
相关论文
共 50 条
  • [1] Barriers to Engagement in Opioid Use Disorder Treatment After Buprenorphine Induction
    Simpson, Scott A.
    Hordes, Melissa
    Blum, Joshua
    Rinehart, Deborah
    Al-Tayyib, Alia
    [J]. JOURNAL OF ADDICTION MEDICINE, 2022, 16 (04) : 479 - 482
  • [2] Medications for Opioid Use Disorder During Incarceration
    McDermott-Winger, Erin R.
    Latham, Christine L.
    [J]. JOURNAL OF ADDICTIONS NURSING, 2022, 33 (03) : 182 - 190
  • [3] Medications for opioid use disorder during incarceration and post-release outcomes
    Lara Cates
    Aaron R. Brown
    [J]. Health & Justice, 11
  • [4] Medications for opioid use disorder during incarceration and post-release outcomes
    Cates, Lara
    Brown, Aaron R.
    [J]. HEALTH & JUSTICE, 2023, 11 (01)
  • [5] Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder
    Fiddian-Green, Alice
    Gubrium, Aline
    Harrington, Calla
    Evans, Elizabeth A.
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (15)
  • [6] Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts
    Chatterjee, Avik
    Weitz, Michelle
    Savinkina, Alexandra
    Macmadu, Alexandria
    Madushani, R. W. M. A.
    Potee, Ruth A.
    Ryan, Danielle
    Murphy, Sean M.
    Walley, Alexander Y.
    Linas, Benjamin P.
    [J]. JAMA NETWORK OPEN, 2023, 6 (04)
  • [7] Opioid Use Disorder Medications After Hospitalization-Rethinking Engagement in Care
    Englander, Honora
    [J]. JAMA INTERNAL MEDICINE, 2024, 184 (09) : 1115 - 1116
  • [8] Sustained-release Oral Hydromorphone for the Treatment of Opioid Use Disorder
    Braithwaite, Vivian
    Fairgrieve, Christopher
    Nolan, Seonaid
    [J]. JOURNAL OF ADDICTION MEDICINE, 2020, 14 (04) : 345 - 347
  • [9] Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review
    Katherine Mackey
    Stephanie Veazie
    Johanna Anderson
    Donald Bourne
    Kim Peterson
    [J]. Journal of General Internal Medicine, 2020, 35 : 954 - 963
  • [10] Probation clients' barriers to access and use of opioid use disorder medications
    Reichert, Jessica
    Gleicher, Lily
    [J]. HEALTH & JUSTICE, 2019, 7 (01)